Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MBX-2044 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| MBX-2044 1.5 mg | EXPERIMENTAL | - |
| MBX-2044 4.5 mg | EXPERIMENTAL | - |
| MBX-2044 15 mg | EXPERIMENTAL | - |
| MBX-2044 30 mg | EXPERIMENTAL | - |
| MBX-2044 60 mg | EXPERIMENTAL | - |
| MBX-2044 90 mg | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| MBX-2044 | DRUG | MBX-2044 1.5 mg one capsule daily for 14 days |
| Placebo for MBX-2044 | DRUG | Placebo Intervention |
Inclusion Criteria: * Type 2 diabetes previously controlled with up to one or two non-TZD hypoglycemic agents including sulfonylureas (e.g., glyburide, glipizide, glimeprimide), meglitinides (e.g., Prandin®, Starlix®), metformin (e.g., Glucophage®), α-glucosidase inhibitors (e.g.,acarbose, miglitol...
MBX-2044 is an investigational small molecule being developed for the treatment of Type 2 Diabetes Mellitus. It is currently in Phase 2 clinical development and has been studied in a completed clinical trial in patients with Type 2 Diabetes Mellitus.
MBX-2044 is being developed by Gilead Sciences, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol GILD. The drug is currently in Phase 2 clinical development for Type 2 Diabetes Mellitus.
MBX-2044 is in Phase 2 clinical development. It has completed one Phase 2 clinical trial, and no active trials are currently listed for the drug. It remains an investigational drug and has not been approved by regulatory authorities.
MBX-2044 has one completed clinical trial, NCT00422487, titled "Safety and Tolerability Study of MBX-2044 in Patients With Type 2 Diabetes." This was a Phase 2, randomized, double-blind, placebo-controlled study conducted in the United States with 60 participants.
MBX-2044 is not FDA approved. It is an investigational drug currently in Phase 2 clinical development for Type 2 Diabetes Mellitus. The drug has completed one clinical trial but has not yet received regulatory approval.